As previously reported, Guggenheim analyst Whitney Ijem initiated coverage of Arcturus Therapeutics with a Buy rating and $19 price target. Ijem views the company's proprietary mRNA + LNP platform as differentiated from others in the space and believes it has the potential to overcome some of the hurdles that have hindered the development of mRNA therapeutics so far, the analyst tells investors. Initial clinical data from the company's lead asset, ARCT-810 for OTC deficiency, gives the company "a near-term, high profile catalyst," add the analyst, who believes early animal data "bodes well."